Ankylosing spondylitis (AS) belongs to a common group of arthritides called spondyloarthopathies (SpA). AS targets primarily the spine and pelvis and is characterized histopathologically by entheseal infl am mation. Disease progression in AS is characterized by excessive bone formation (ankylosis) that gradually bridges the gap between joints, eventually fusing joints and causing stiffness, pain, signifi cant morbidity, and increased mortality [1] .
Genetic overlap between ankylosing spondylitis and gut disease
Strong genetic overlap exists between AS and IBD, and the two conditions commonly occur together in families [4] . Danoy and colleagues [5] (2010) studied genes known to be associated with IBD in a large AS cohort. New loci and genes were identifi ed, and of particular note were genes involved in the interleukin-23 (IL-23) pathway, such as STAT3, IL-23 receptor (IL23R), and IL12B (which encodes IL-12p40, the share subunit of IL-23 and IL-12) [5] [6] [7] . How these genetic lesions infl uence gut homeostasis and function remains unclear. Major diff er ences also exist between the genetics of IBD and AS, and AS has shown no association to date with NOD2/CARD15 or the autophagy gene ATG16L1, which are major susceptibility factors in IBD, whereas IBD shows no association with HLA-B or ERAP1, which are the strongest AS susceptibility genes [8] . Although no asso ciation has been shown with NOD2/CARD15 and AS specifi cally, polymorphisms in NOD2/CARD15 have been associated with an increased risk of gut disease in patients with SpA [9] .
The gut, barrier regulation, and intestinal epithelial cells
Homeostasis of the normal microbial fl ora in the gut is essential for intestinal health. Th e gastrointestinal tract is heavily populated with microbes and is the primary site for interaction between these microorganisms and the immune system [10, 11] . Furthermore, microbes found in the gut help to shape host immune systems from an early age. Th e incomplete development of the immune system in neonates and under germ-free (GF) conditions tells us that microbiota sculpt the host immune system [12, 13] .
Maintenance of intestinal and microbial homeostasis is increasingly recognized as playing a pivotal role in overall health [14] , and dysregulation of either gut or microbial homeostasis may play a role in autoimmunity. Physiological processes in the host that maintain gut homeo stasis and respond to perturbance in the gut micro environ ment involve both the adaptive and innate immune system and the barrier function of the intestines themselves.
Abstract
It is increasingly clear that the interaction between host and microbiome profoundly aff ects health. There are 10 times more bacteria in and on our bodies than the total of our own cells, and the human intestine contains approximately 100 trillion bacteria. Interrogation of microbial communities by using classic microbiology techniques off ers a very restricted view of these communities, allowing us to see only what we can grow in isolation. However, recent advances in sequencing technologies have greatly facilitated systematic and comprehensive studies of the role of the microbiome in human health and disease. Comprehensive understanding of our microbiome will enhance understanding of disease pathogenesis, which in turn may lead to rationally targeted therapy for a number of conditions, including autoimmunity.
The physical barrier
Th e human gastrointestinal tract is not a complete barrier. It is composed of a single layer of intestinal epithelial cells (IECs), which form a physical barrier separating the intestinal lumen from the lamina propria ( Figure 1 ). IECs secrete soluble factors that are crucial to intestinal homeostasis, such as mucins and anti-microbial peptides, including lysozymes, defensins, cathelicidins, lipocalins, and C-type lectins such as RegIIIγ [15] [16] [17] . Release of these molecules into luminal crypts is thought to prevent microbial invasion into the crypt microenvironment as well as limit bacteria-epithelial cell contact [16, 18] . Compared with healthy controls, Crohn's disease patients with active disease have pronounced decreases in the human α-defensins DEFA5 and DEFA6 in the ileum, resulting in altered mucosal function and overgrowth or dysregulation of commensal microbial fl ora [18, 19] . Conversely, overexpression of anti-microbials, including α-defensins, are reported in sub-clinically infl amed ileum of AS patients compared with Crohn's disease patients and healthy controls [20] . However, it remains unclear whether changes in innate mucosal defenses lead to alterations in gut-resident microbial fl ora or whether early changes in the microbiome sculpt intestinal host responses. Furthermore, depletion of the mucin layer leads to an IBD-like phenotype and endoplasmic reticu lum stress, potentially driving IL-23 produc tion [21] . IL-23 excess alone is suffi cient to induce spondyloarthritis in mice [22] , and genetic evidence, in particular, indicates that the cytokine plays a key role in the development of spondyloarthritis in humans.
Permeability and disease
Th e dynamic crosstalk between IECs, microbes, and the local immune cells is fundamental to intestinal homeostasis but is also suggested to play a part in disease pathogenesis [23] . In IBD and celiac disease, tight junctions are dysregulated, causing increased permeability between IECs, resulting in a 'leaky gut' [24, 25] . Studies looking at fi rst-degree relatives of patients with AS showed that they too have increased gut permeability, so it is likely that there is an underlying genetic process operating in the gut [26, 27] .
The immune barrier
Th e complexity of the intestinal immune system is the subject of many reviews, but here we will focus on some intestinal immune populations that are believed to be important in rheumatic disorders.
Innate immunity
Dendritic cells (DCs) densely populate the intestinal lamina propria and form a widespread microbe-sensing network. DCs recognize a broad repertoire of bacteria, sensing with receptors such as Toll-like receptors (TLRs) and monitoring the bacteria on the mucosal surface [28] . Intestinal DCs orchestrate production of intestinespecifi c IgA to limit bacterial contact with the intestinal epithelial cell surface [29] . Activated DCs can secrete a number of cytokines and chemokines, including IL-23 and IL-6, that are involved in infl am mation and migration of DCs [30] .
Macrophages patrol the gastrointestinal systems in high numbers. Th ey frequently come in contact with 'stray' bacteria, including commensals that have breached the epithelial cell barrier. Macrophages phagocytose and rapidly kill such bacteria by using mechanisms that include the production of antimicrobial proteins and reactive oxygen species [31] . Intestinal macrophages have several unique characteristics, including the expression of the anti-infl ammatory cytokine IL-10, both constitutively and after bacterial stimulation [32, 33] . Th is makes intestinal macrophages non-infl ammatory cells that still have the capacity to phagocytose. Th e importance of this pathway is highlighted by the fact that loss-of-function mutations in IL10R lead to early-onset IBD [34] . However, not all intestinal macrophages are non-infl ammatory. In patients with Crohn's disease, a population of intestinal macrophages secrete infl ammatory cytokines such as IL-23, tumor necrosis factor-alpha (TNF-α), and IL-6. Th ese macrophages contribute to an infl ammatory microenvironment in patients with Crohn's disease [35] . Intestinal macrophages also play a role in the restoration of the physical integrity of the epithelial cell barrier following injury or bacterial insult [24] . Re-establishing this barrier after injury is imperative to avoid bacterial penetration and sepsis in such a microbe-laden environment [36] . , which recognizes microbial β-glucans. Expression of these receptors supports a role for γδ T cells in early responses to microbes. Of further relevance, we and others have recently confi rmed that CARD9, part of the dectin-1 response pathway, is a susceptibility gene for AS and IBD [44] . γδ T cells are potent producers of infl ammatory cytokines such as inter feron-gamma (IFN-γ), TNF-α, and IL-17 [45, 46] . Th ey are pathogenic in the collagen-induced arthritis model [47] and mouse models of colitis [48] , and IL-17-secreting γδ T cells are expanded in patients with AS [49] . Intraepithelial γδ T cells also play an important role in modulating intestinal epithelial growth through secretion of fi broblast growth factor [50] . Alterations to γδ T-cell numbers or functions, therefore, may have profound eff ects on intestinal health.
Adaptive immunity

Natural killer T cells
NKT cells are characterized by expression of an invariant TCR, Vα24Jα18 in humans and the orthologous Vα14Jα18 in mice. NKT cells recognize glycolipid structures presented to them by the non-classic antigenpresenting molecule CD1d. Like γδ T cells, NKT cells are rapid responders to antigenic stimuli and are capable of producing a range of immunoregulatory cytokines [51] [52] [53] [54] . Within the gut, NKT cells are protective in T helper 1 (T H 1)-mediated models of IBD but are pathogenic in T H 2 models [55, 56] . Recently, it has been shown that microbial stimulation of NKT cells in the gut of mice aff ects NKT cell phenotypic and functional maturation [57, 58] . Given that NKT cells have protective roles in models of arthritis [59] and SpA [60] , their functional maturation in the gut provides evidence for a role for mucosal T-cell priming in infl ammatory joint disease.
Mucosa-associated invariant T cells
MAIT cells are a population of innate-like T cells that are abundant in human gut, liver, and blood and secrete a range of infl ammatory cytokines such as IL-17 and IFN-γ in response to antigenic stimulation [61] [62] [63] . Like NKT cells, MAIT cells bear an invariant TCR (Vα7.2 in humans) that recognizes antigen presented by the nonclassic MHC-like molecule, MR1 [64] . In blood, MAIT cells display a memory phenotype [63] and express the transcription factor ZBTB16 [65] , allowing them to rapidly secrete cytokine in response to antigenic stimuli. Furthermore, they express high levels of IL-23R [66] .
MAIT cells react to a wide range of microbial stimuli, including Gram-positive and Gram-negative bacteria as well as yeasts [61, 62] . Although the precise role of MAIT cells in maintenance of the mucosal barrier remains unclear, the rapid postnatal expansion of MAIT cells and their acquisition of phenotypic markers of memory likely represent an interaction with developing commensal microfl ora [67] .
Lymphoid tissue inducer-like cells and innate lymphoid cells
LTi-like cells are found in spleen, lymph node, and gut lamina propria. LTi-like cells constitutively express hallmarks of IL-17-secreting cells, including IL-23R, RORγt, AHR, and CCR6 [68] . Stimulation of LTi-like cells with IL-23 induces IL-17 secretion [68] , whereas PMA and ionomycin stimulation invokes secretion of IL-22 [69] . LTi cells appear to be related to an increasingly interesting and heterogeneous population of innate lymphoid [70] . NKp46 + ILCs are involved in host defense against Citrobacter rodentium infection through secretion of IL-22 [71] .
The human microbiome revolution
Together, the multi-factorial components of the immune system shape the microbial population that inhabits the gut and (to an extent) vice versa, with each side pushing to establish a stable state. Understanding the yin and yang of this relationship is at the heart of current microbiome research.
Microbiome refers to the totality of microbes, their genetic elements, and environmental interaction in a defi ned environment [72] . Projects such as the Human Microbiome Project, run by the National Institutes of Health, and the Metagenomics of the Human Intestinal Tract (MetaHit) consortium aim to determine what constitutes a 'normal' or healthy microbiome. Research in this fi eld has recently been greatly accelerated by the development of high throughput sequencing methods for microbial profi ling, which can profi le microbial popu lations whether or not the microbes present can be cultured.
16S rRNA sequencing
16S rRNA is a section of prokaryotic DNA found in all bacteria and archaea. 16S rRNA sequences are used to diff erentiate between organisms across all major phyla of bacteria and to classify strains down to the species level [73] . 16S rRNA sequencing has dramatically changed our understanding of phylogeny and microbial diversity because it provides an unbiased assessment of the microbiome and is not restricted by the ability to culture the bacteria present.
Further improvements in sequencing technologies have reduced the need for targeted studies such as 16S sequencing and enabled high-throughput shotgun sequencing. Th is latter type of sequen cing randomly samples all genes present in a habitat rather than just 16S rRNA. Shotgun sequencing provides more information about the microbiome than just the 16S characterization, which is of particular benefi t in determining the functional capacity of the microbial community rather than just its phylo geny. However, shotgun sequencing is more complex to analyze, owing in part to the challenge of distinguishing between host and bacterial genomic material, and requires far more sequencing to be performed. Th erefore, most studies to date have relied on 16S rRNA sequencing approaches.
Advances in tools for metagenomic studies
Several sequencing technologies have been developed for human genetic studies and have since been adapted to metagenomics. Th e Roche 454 sequencing platform (Roche, Basel, Switzerland) uses large-scale parallel pyrosequencing to produce reads of between 450 and 1000 base pairs (bp) in length. Read lengths produced by the 454 platform are well suited to 16S rRNA amplicon metagenomics studies as well as shotgun sequencing as they are easily aligned to reference bacterial genetic data sets. Sequencing plat forms from Illumina (San Diego, CA, USA), the HiSeq2000 and MiSeq, produce shorter reads than the Roche 454. Th e HiSeq was designed primarily for human genomic sequencing, and current chemistry produces 100-bp paired-end reads. Illumina sequencing is best suited for shotgun sequencing or indexed amplicon sequencing of multiple samples.
Th is is a rapidly developing fi eld. Advances in chemistry are predicted to increase both read lengths and output for both of these platforms over the next 12 to 24 months, particularly for the Illumina platforms that are less mature than the Roche 454. New platforms coming to the market are likely to have a major impact on metagenomics study design. For example, the Pacifi c Biosciences sequencing technology (Pacifi c Biosciences, Menlo Park, CA, USA) provides reads of approximately 3,000 bases, which will make it particularly suited to this fi eld, despite its lower overall output (approximately 100 Mb of sequence per run). Life Technologies Ion Torrent technology (Life Technologies, Grand Island, NY, USA) is reported to produce up to 400 base reads and up to 1 Gb of sequence per run. Th e relative positions of these competing technologies in metagenomics have yet to be established.
The normal human gut microbiome
To date, only a handful of studies have examined in any depth the function as well as the composition and diversity of the human gut microbiome. Two large studies interrogating and cataloguing microbiomes from various regions of the body in health and disease have been undertaken by the National Institutes of Health Human Microbiome Project in the US and the European MetaHit project [74] [75] [76] . Th e European MetaHit consortium combined published data sets from around the world and added 22 newly sequenced fecal metagenomes from four diff erent European countries. Th ey identifi ed three robust clusters, termed 'enterotypes' , that were not nation-or continent-specifi c. Th ese enterotypes characterized the microbial phylogenetic variation as well as the function variation of the clusters at gene and functional class levels [74] . Each enterotype had a dominant bacterial genus: enterotype 1 was dominated by the genus Bacteriodes, enterotype 2 by Prevotella, and enterotype 3 by Ruminococcus. Th e three enterotypes were also shown to be functionally diff erent. For example, enterotype 2, which is Prevotella-dominant, also contains Desfulfovibrio, which may act in synergy with Prevotella to degrade mucin glycoproteins present in the mucosal layer of the gut. It may be that diff erent enterotypes may be associated with diseases such as obesity and IBD rather than necessarily specifi c bacterial species, given their diff ering functional capacities. Further studies will be required to determine whether enterotypes are consis tently found in expanded data sets and in studies of intestinal biopsies as well as the fecal samples used in the MetaHit study.
The microbiome in immune-mediated arthritis
Th e major fi ndings of microbial profi ling studies in major immune-mediated diseases associated with arthritis are summarised in Table 1 . To date, no study investigating the gut microbiome by using sequencing-based methods in AS has been reported. Many studies largely using antibody tests have suggested an increased carriage of Klebsiella species in patients with AS, but this has not been universally supported [77] . One study using denaturing gradient gel electrophoresis to profi le the microbiome by using fecal samples found no diff erences between AS cases and healthy controls [78] .
Rheumatoid arthritis (RA) is the only infl ammatory arthritis for which modern metagenomic studies have been reported. Community profi ling studies of gut fl ora of patients with RA reveal diff erences in the composition of gut microbiota of patients with RA compared with those of healthy controls, and a lower abundance of Bifi dobacterium and Bacteroides bacteria was observed in RA cases [79, 80] . However, these studies used fecal samples and not intestinal biopsies, possibly infl uencing the populations observed [81] . Also, microbial profi ling data suggest that gingival infection may be important, particularly in anti-citrullinated peptide antibody-positive RA, although the studies suggesting this have generally used antibody tests rather than sequencingbased approaches (reviewed in [82] ).
Several lines of evidence indicate that the gut microbiome plays an important role in IBD, including the association of genes involved in mucosal immunity with IBD (such as CARD15, CARD9, IL-23R, and ATG16L1), the therapeutic eff ect of antibiotics on the condition, and the benefi cial eff ect of fecal stream diversion in Crohn's disease. Previous studies of human IBD have been undertaken by using standard culture techniques (for example, [83] ) or molecular analysis (for example, [84, 85] ). Th ese studies noted alterations in intestinal microbiota when compared with non-IBD patients, a fi nding recently confi rmed by using 16S rRNA sequencing of intestinal biopsies [86] . Th is sequencing study, however, did not identify an IBD-specifi c microbial profi le, perhaps because of insuffi cient resolution of the sequencing performed or small sample size (12 patients and 5 controls). Much larger studies will be required to dissect the relationship between the host genetic factors determining risk of IBD and the gut microbiome.
Th e microbiome is thought to play a signifi cant role in psoriasis, another AS-related condition. It has long been suggested that streptococcal infection, especially throat infections, may trigger psoriasis in a genetically susceptible individual [87] . Recent studies using 16S rRNA sequencing have found signifi cant diff erences between the cutaneous microbiota of psoriasis cases and controls and in involved and control skin in psoriasis cases, and less staphylococci and propionibacteria have been observed in cases and in aff ected skin [88] . Again, further studies will be required to determine whether there is a particular microbial profi le or specifi c bacterial species involved in psoriasis.
Th ese studies are thus consistent with the hypothesis that the microbiome contributes to the etiopathogenesis of immune-mediated arthritis or seronegative diseases like IBD and psoriasis. However, at this point, there is no defi nitive evidence of specifi c bacterial infections or changes in microbial profi le that play a causative role in these conditions (with the exception of reactive arthritis).
Chicken and the egg
Whether the changes noted in these early metagenomic studies of immune-mediated disease are a consequence of disease or are involved in its development or persistence is unclear. Th is distinction may prove impossible to dissect in human studies, but considerable evidence in studies in mice supports a role for the microbiome in driving immune-mediated diseases.
In the B27 rat model of AS, rats housed under GF conditions did not develop disease [89] , demonstrating that microbes in this model are important for disease penetrance. In contrast, in the New Zealand black model of systemic lupus erythematosus, mice maintained under GF conditions produced higher levels of antinuclear antibodies and developed worse disease [90] , demonstrating a protective role for commensal microbes.
Given the IL-17/IL-22 cytokines, which are of relevance to AS, IBD, and psoriasis in particular, strong evidence from murine studies indicates that interaction between the gut microbiome and the host determines the overall level of activation of the immune cells producing these cytokines. Segmented fi lamentous bacteria (SFB) are com mensal bacteria that induce IL-17 secretion. Mice lacking SFB have low levels of intestinal IL-17 and are susceptible to infection with pathogenic Citrobacter spp. Restoration of SFB in these mice increased the number of gut-resident IL-17-producing cells and enhanced resistance to infection [12] . Salzman and colleagues [91] illustrated that α-defensins modulate mucosal T-cell response by regulating the composition, but not the total numbers, of bacteria in the intestinal microbiome.
Examin ing the intestinal microbiota of mice expressing the human α-defensin gene, they demonstrated significant α-defensin-dependent alterations in commensal composition, leading to a loss of SFB and fewer IL-17-producing lamina propria T cells [91] . Furthermore, using recolonization studies, investigators recently demonstrated that, in neonatal mice, commensal microbes infl uence invariant NKT (iNKT) cell intestinal infi ltration and activation, establishing mucosal iNKT cell tolerance to later environmental exposures [92] .
Th e mechanism by which the microbiome infl uences IL-17-producing cell activation is still being determined. Ivanov and colleagues [12] demonstrated that serum amyloid A, produced in the terminal ileum, can induce T H 17 diff erentiation of CD4 + T lymphocytes. It has also been shown that development of T H 17 lymphocytes in the intestine is stimulated by microbiota-induced IL-1β (but not IL-6) production [93] . Colonization with Clostridial species has been shown to stimulate intestinal transforming growth factor-beta (TGF-β) production, in turn increasing IL-10 + CTLA4 high Treg (regulatory T) activation [94] . Clostridial coloniza tion of neonatal mice reduced severity of induced colitis by using dextran sulphate sodium or oxazolone and reduced serum IgE levels in adulthood. So it is likely that alterations to the gut microfl ora or invasion of the gut by pathogenic bacteria infl uences the balance of IL-17-and IL-22-producing cells and other immune cells, infl uen cing susceptibility to local and systemic immune-mediated disease.
Th e above studies highlight that changes in the microbiome can lead to infl ammation which may have farreaching eff ects and demonstrate experimental approaches by which fi ndings of metagenomic studies in mice and humans can be explored to successfully dissect the role of the microbiome in human immune-mediated diseases.
Conclusions
Th e human gut microbiome is a dynamic and complex ecosystem that is only now beginning to be understood. 
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